Last €5.88 EUR
Change Today -0.07 / -1.18%
Volume 12.5K
As of 11:29 AM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

biohit oyj-b (BIOBV) Snapshot

Open
€6.00
Previous Close
€5.95
Day High
€6.00
Day Low
€5.88
52 Week High
01/13/14 - €8.17
52 Week Low
02/27/14 - €5.42
Market Cap
81.1M
Average Volume 10 Days
16.0K
EPS TTM
€-0.44
Shares Outstanding
11.0M
EX-Date
04/15/14
P/E TM
--
Dividend
€0.72
Dividend Yield
12.30%
Current Stock Chart for BIOHIT OYJ-B (BIOBV)

Related News

No related news articles were found.

biohit oyj-b (BIOBV) Related Businessweek News

No Related Businessweek News Found

biohit oyj-b (BIOBV) Details

Biohit Oyj, a biotechnology company, manufactures diagnostics products, analysis systems, and acetaldehyde binding products primarily in Europe, North and South America, and Asia. The company’s products include the blood sample-based GastroPanel tests for the diagnosis of stomach diseases and associated risks, including gastric cancer. It also offers other enzyme-linked immunosorbent assay tests (ELISA), such as celiac disease panels intended for the diagnosis, and treatment follow-up of celiac disease and dermatitis herpetiformis; inflammatory bowel disease panels for the detection and differentiation of Crohn´s disease and ulcerative colitis; cellular fibronectin tests; and anti-Telomere IgG ELISA for the diagnosis of systemic lupus erythematosus. In addition, the company provides quick tests for the diagnosis of lactose intolerance, and Helicobacter pylori infection in connection with gastroscopy; Colon-View examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer; and POC tests diagnosing celiac disease from fingerbrick blood sample. Further, it offers acetaldehyde binding products, including acetium capsules intended for persons with a low-acid or anacidic stomach, and acetium lozenge for removing acetaldehyde in smoker's saliva; and monoclonal antibodies for research and clinical use in the area of cellular pathology, neurobiology, and oncology, as well as in research of human gastric biomarkers. Additionally, the company provides microplate readers and strip washers for diagnostics, research, and clinical laboratory instrumentation; and mechanical and electronic pipettes, and disposable pipette tips, as well as analyses carcinogenic acetaldehyde in foodstuff, and non-alcoholic and alcoholic beverages. It serves private doctors, health centers, and reference and service laboratories, as well as research institutions and hospitals. The company was founded in 1988 and is headquartered in Helsinki, Finland.

47 Employees
Last Reported Date: 05/8/14
Founded in 1988

biohit oyj-b (BIOBV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biohit oyj-b (BIOBV) Key Developments

Biohit Oyj Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Biohit Oyj reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net sales of EUR 0.9 million compared to EUR 0.6 million for the same period a year ago. Operating loss, continuing operations was EUR 1.2 million compared to EUR 1.0 million for the same period a year ago. Loss before taxes was EUR 1 million compared to EUR 1.0 million for the same period a year ago. Profit for the period was EUR 2.2 million compared to loss for the period of EUR 1.0 million for the same period a year ago. Undiluted loss per share was EUR 0.07 compared to WUR 0.07 a year ago. Net cash flow used in operating activities was EUR 0.6 million compared to EUR 0.8 million for the same period a year ago. Investments in tangible and intangible assets were EUR 0.1 million compared to EUR 0.1 million for the same period a year ago.

Biohit Amends Articles of Association

Biohit at the Annual General Meeting held on April 14, 2014 decided that the paragraph 3 of the Articles of Association is amended by deleting references to maximum and minimum capital as well as to maximum and minimum number of the shares. In addition, In accordance with the proposal by the Board of Directors, the AGM decided that paragraph 4 of the Articles of Association is replaced by stipulation that the company’s share has no nominal value. The new wording of the paragraph 3 of the Articles of Association is: The company’s shares are divided into Series A shares and Series B shares. In a General Meeting, holders of Series A shares shall be entitled to 20 votes per share and Series B shares to one vote per share.

Biohit Elects PricewaterhouseCoopers Oy as Auditors

Biohit announced at its Annual General Meeting held on April 14, 2014, shareholders elected authorised public accountants PricewaterhouseCoopers Oy as the company’s auditors, with APA Pasi Karppinen as the head auditor, until the end of the next AGM.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOBV:FH €5.88 EUR -0.07

BIOBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOBV.
View Industry Companies
 

Industry Analysis

BIOBV

Industry Average

Valuation BIOBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.7x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHIT OYJ-B, please visit www.biohithealthcare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.